Antibody-drug conjugates: paving the future of oncology clinical development
European Pharmaceutical Review
OCTOBER 26, 2023
In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development. Podder continued, highlighting however that the current challenges of ADCs include drug resistance and their complex and costly manufacturing processes.
91 
Let's personalize your content